RetInSight
Overview
RetInSight, a Topcon Healthcare company, is a leader in AI-based ophthalmic software, empowering eye care providers, academic institutions, and the eye care industry to reimagine clinical care with advanced artificial intelligence solutions. The company leverages data to deliver novel insights into unmet diagnostic needs associated with diseases that manifest in the retina.
As a spin-off of the Medical University of Vienna, RetInSight stands on a foundation of over a decade of global academic leadership in AI-based retinal image analysis. Their interdisciplinary team is dedicated to preserving eyesight throughout a lifetime by bringing AI to the eye. The company’s mission is to revolutionize ophthalmology through reliable, affordable, and easy-to-use AI-based medical software that enables timely diagnosis, accurate monitoring, and personalized treatment of retinal diseases.
RetInSight develops and delivers its solutions and services on a comprehensive and flexible AI platform, offering cloud-based AI modules tailored to various needs, including stand-alone use, device integration, and PACS integration.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-driven GA Monitor for Geographic Atrophy assessment and treatment evaluation
- AI-powered Fluid Monitor for precise fluid quantification and treatment response analysis in nAMD, DME, RVO
- Automated segmentation and quantification of retinal fluid types (IRF, SRF, PED) and GA lesions
- Customized, one-page PDF reports for physicians and patients
- Seamless integration into current OCT routine and PACS systems (Heidelberg Engineering Spectralis OCT with HEYEX 2.6 / AppWay; Topcon Triton OCT with Harmony)
- Cloud-based AI modules with stand-alone, device integration, and PACS integration options
- Dynamic follow-up charts for fluid dynamics and disease progression visualization
- Support for clinical studies and pharmaceutical trials (cAIre - center for AI reading excellence)
Use Cases
- Revolutionizing management of Geographic Atrophy (GA)
- Monitoring and analyzing fluid levels in neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO)
- Improving clinical efficiency and workflow for eye care professionals
- Advancing scientific knowledge and drug development through collaborative clinical research and retrospective analysis
- Supporting timely diagnosis, accurate monitoring, and personalized treatment of retinal diseases
- Enhancing patient communication and compliance with easy-to-understand reports
Details
| Category | Ophthalmology AI |
| Pricing | Not publicly disclosed. |
| Deployment | Cloud-based AI modules; Stand-alone, device integration, and PACS integration (Heidelberg Engineering Spectralis OCT with HEYEX 2.6 / AppWay; Topcon Triton OCT with Harmony). |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated RetInSight was FDA approved in 2022 for precise analysis of OCT images and retinal disease monitoring. It has also received regulatory approvals as Class IIa medical devices from Australia’s Therapeutic Goods Administration (TGA) and Medsafe in New Zealand in August 2025, and holds MDR CE-certification in Europe. |
| Integrations | |
| EHR | Not specified |
| Specialties | Ophthalmology |
What the Web Says
RetInSight is an AI-powered software that analyzes Optical Coherence Tomography (OCT) images to detect and monitor retinal diseases like neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and geographic atrophy (GA). It aims to improve efficiency in clinical routines, provide more precise measurements than human graders, and offer real-time insights for treatment decisions. The system has received EMA approval in Europe and FDA approval in the US for certain applications.
Overall: PositiveStrengths
- Increases efficiency and reduces repetitive work for physicians.
- Provides precise quantification of fluid levels and other biomarkers in nanoliters, which can be superior to human analysis.
- Enables more accurate determination of treatment initiation and customizable treatment approaches.
- Offers comprehensive reporting and real-time decision-making based on fluid volume changes.
- Supports multiple OCT systems and is compatible with any web browser, allowing for user-friendly integration.
- Aids in scientific research and pharmaceutical trials by providing advanced data analytics and supporting AI-powered drug development.
Limitations
- Potential for over-referrals due to lower specificity and a high false positive rate in some AI screening tools for retinal conditions (general AI in ophthalmology concern, not specific to RetInSight).
- Scarcity of head-to-head studies comparing different AI models in ophthalmology, making it difficult to understand expected performance in real-world scenarios and address potential biases.
- General concern about retinal scans being charged without prior consent or clear explanation of separate costs in some practices (general patient experience, not specific to RetInSight).
Based on reviews from: RetInSight (retinsight.com), Eyes On Eyecare, Healio, Optometry Times, PubMed Central (PMC), Reddit, Capterra, Trustpilot
Last updated: 2026-07-24
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate RetInSight
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for RetInSight.
Topcon and RetInSight Join Forces: AI-Powered Retinal Biomarkers Now Seamless with OCT Imaging
Deepak Sobti MD
